Radiation oncology, five years and beyond: An evidence-and-capital global framework for evaluating six emerging innovations
Visualized Cancer Medicine · 2026 · 7 · 4
DOI: 10.1051/vcm/2026004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Visualized Cancer Medicine, online erschienen am 24.07.2026. Verfasst von Robert C. Miller. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiation oncology is poised for a decade of unusually rapid technological and biological change. Six innovations are converging on the clinic: FLASH radiotherapy, adaptive radiotherapy with advanced imaging, artificial intelligence and machine learning in treatment planning, theranostics with targeted radionuclide therapy, spatially fractionated radiotherapy using GRID and LATTICE techniques, and continuing enhancements in particle therapy with protons and heavy ions. Each is biologically compelling, but they will not reach patients at the same speed or in equal numbers. This review proposes an evidence-and-capital framework for evaluating these innovations along four axes – physical principle, biological rationale, current clinical evidence, and dominant adoption barrier – and ranks them by anticipated population-level impact over the next five years. Capital intensity emerges as the principal determinant of diffusion: innovations layered onto existing linear accelerators (artificial intelligence, spatially fractionated radiotherapy) or onto existing nuclear medicine infrastructure (theranostics) will scale globally, whereas innovations requiring new bunkers, magnetic-shielded vaults, or dedicated accelerators (adaptive radiotherapy, FLASH, particle therapy) will remain concentrated in well-resourced centres. A low anticipated diffusion ranking is not a judgement on intrinsic clinical value: several capital-intensive modalities deliver substantial benefit for selected patients even where population-level reach is limited, and the framework distinguishes throughout between intrinsic efficacy and expected accessibility. The resulting equity gap is not primarily a scientific problem but an infrastructural one. Recognising this asymmetry should inform departmental investment, training curricula, multinational cooperative-group trial design, and health-system policy on capital subsidy and consortium models. The framework is intended for radiation oncologists, medical physicists, and cancer scientists evaluating where to invest finite institutional resources.
Zitieren
APA
Miller, R. C. (2026). Radiation oncology, five years and beyond: An evidence-and-capital global framework for evaluating six emerging innovations. Visualized Cancer Medicine, 7, 4. https://doi.org/10.1051/vcm/2026004
Vancouver
Miller RC. Radiation oncology, five years and beyond: An evidence-and-capital global framework for evaluating six emerging innovations. Visualized Cancer Medicine. 2026;7:4. doi:10.1051/vcm/2026004
BibTeX
@article{Miller2026,
author = {Miller, Robert C.},
title = {Radiation oncology, five years and beyond: An evidence-and-capital global framework for evaluating six emerging innovations},
journal = {Visualized Cancer Medicine},
year = {2026},
volume = {7},
pages = {4},
doi = {10.1051/vcm/2026004}
}
EUVIMED